Previous 10 | Next 10 |
Invitae Appoints William H. Osborne to its Board of Directors PR Newswire – Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions – SAN FRANCISCO , ...
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
Summary NVTA Q4 cash balance remained flat year-over-year at $555M, with 2022 revenue declining by $4M to $122M. Shares appreciated 25% after last week's Q4 purview on optimism over management's ability to trim operating costs, which would provide NVTA with sufficient runway to execute ...
Summary Despite its price surge, EXAS's valuation remains aligned with industry averages. EXAS has one of the clearest profitability paths in a market characterized by heavy losses stemming from aggressive growth initiatives. We might see some profit-taking in the coming weeks, but ...
Invitae Corporation (NVTA) 41st Annual JPMorgan Healthcare Conference January 11, 2023 12:00 PM ET Company Participants Kenneth Knight - Chief Executive Officer Dr. Bob Nussbaum - Chief Medical Officer Roxi Wen - Chief Financial Officer Dr. Valerie Montgomery Rice ...
Invitae ( NYSE: NVTA ) expects prelim Q4 revenue of ~$122M vs. analysts estimates of $121.41M. Revenue is expected to fall from $126M a year ago due to the exited businesses and geographies. The medical genetics company generated revenue of approximately $516M (consensus: $515...
Invitae Reports Preliminary 2022 Financial Results PR Newswire — Approximately 12% growth year-over-year in revenues — — Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash — — Cash burn ...
Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...
Buying in a bear market can be a great move if you pick quality stocks and hold them for the long haul. Some stocks struggled so badly over the past year that they are trading around multiyear lows. Three stocks that fit that criteria and while still generating positive growth numbers include...
Invitae to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight , president & chief executive office...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...